Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 2/20 | 0.30 |
| ▸ | GABRD | O14764 | 2/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1461506 | 0.84 | SLC1A3 (0.32) | SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL9323986 | 0.83 | SLC7A5 (0.46) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| Ammonia Solution, Strong SCHEMBL28494050 | 0.82 | SLC1A3 (0.31) | SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL2720464 | 0.81 | SLC7A5 (0.44) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| SCHEMBL2886770 | 0.80 | — | — | |
| SCHEMBL12211509 | 0.80 | — | — | |
| SCHEMBL25395192 | 0.79 | SLC7A5 (0.42) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| SCHEMBL28859296 | 0.79 | SLC7A5 (0.42) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| SCHEMBL28859298 | 0.79 | SLC7A5 (0.42) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| SCHEMBL28442557 | 0.79 | DPP4 (0.41) | DPP4FAPDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115141131-A | 3,4-diacetyl-2,5-dimethylpyrrole compound and preparation method and application thereof | 湖北中烟工业有限责任公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-113831391-A | Dipeptide compound exerting rapid antidepressant effect and application thereof | 南京医科大学 | 2021-12-24 | — | — | CN | disclosed |
| US-8133904-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| WO-2011018771-A2 | PROCESS FOR THE PREPARATION OF VALGANCICLOVIR HYDROCHLORIDE | RANBAXY LABORATORIES LIMITED (IN) | 2011-02-17 | — | — | WO | disclosed |
| CN-101795569-A | Cannabinoid receptor antagonists/inverse agonists for the treatment of obesity | JENRIN DISCOVERY | 2010-08-04 | — | — | CN | disclosed |
| EP-2182807-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | Jenrin Discovery (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009033125-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090069329-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2009-03-12 | — | — | US | disclosed |
| EP-1210360-A4 | COMPOUNDS USEFUL TO MIMIC PEPTIDE BETA-STRANDS | UNIV CALIFORNIA (US) | 2005-03-02 | — | — | EP | disclosed |
| EP-1210360-A1 | COMPOUNDS USEFUL TO MIMIC PEPTIDE BETA-STRANDS | The Regents of the University of California (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001014412-A1 | COMPOUNDS USEFUL TO MIMIC PEPTIDE BETA-STRANDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-03-01 | — | — | WO | disclosed |
| US-6160122-A | Process for the preparation of a disubstituted thiazole | ABBOTT LABORATORIES (US) | 2000-12-12 | — | — | US | disclosed |
| US-6022989-A | Process for the preparation of an activated amino acid | ABBOTT LABORATORIES (US) | 2000-02-08 | — | — | US | disclosed |
| US-5955582-A | FOR IMMUNOASSAY DIAGNOSIS AND MONITORING OF CONDITIONS LIKE DIABETES | BECKMAN COULTER, INC. (US) | 1999-09-21 | — | — | US | disclosed |
| EP-0854872-A1 | PROCESS FOR THE PREPARATION OF A DISUBSTITUTED THIAZOLE | Abbott Laboratories (US) | 1998-07-29 | — | — | EP | disclosed |
| EP-0854862-A1 | PROCESS FOR THE PREPARATION OF AN ACTIVATED AMINO ACID | Abbott Laboratories (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1998000393-A1 | PROCESS FOR THE PREPARATION OF AN ACTIVATED AMINO ACID | ABBOTT LABORATORIES (US) | 1998-01-08 | — | — | WO | disclosed |
| WO-1998000410-A1 | PROCESS FOR THE PREPARATION OF A DISUBSTITUTED THIAZOLE | ABBOTT LABORATORIES (US) | 1998-01-08 | — | — | WO | disclosed |
| EP-0044710-B1 | SYNTHETIC PEPTIDE SPECIFIC ANTIGENIC DETERMINANT AND METHOD OF MANUFACTURING ANTIGENIC MATERIALS THEREFROM | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1986-04-02 | — | — | EP | disclosed |
| EP-0044710-A1 | Synthetic peptide specific antigenic determinant and method of manufacturing antigenic materials therefrom | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1982-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069329-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | CNR2, CNR1, GPR119 | SLC7A5 4463/4885SLC1A3 2799/4885SLC1A2 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.